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A major problem in cytostatic treatment of malignant tumors is the development 
of drug-resistance. One of the potential mechanisms of resistance is induction of 
drug-inactivating enzymes. The aim of the present study was to evaluate the effects of 
short-term exposure of MCF-7 cells to doxorubicin and oracin on the activities and 
expression of selected carbonyl reducing enzymes. Carbonyl reduction of these 
cytostatic drugs leads to 13-doxorubicinol (doxol) and 11-dihydrooracin (DHO), the 
major metabolites with lower antineoplastic potency compared to the parent drugs. We 
found that short-term (48 h) exposure of MCF-7 cells to low (nM) concentrations of 
doxorubicin or oracin caused a significant elevation of both cytostatics reduction rates. 
In order to identify principal enzyme(s) catalyzing the reduction of doxorubicin and 
oracin, we tested effects of selected inhibitors of aldo-keto reductase AKR1C3 and 
carbonyl reductase CBR1 on doxol and DHO formation. AKR1C3 and CBR1 are 
expressed in human breast cells. We found that the principal enzyme reducing both 
drugs was CBR1, while AKR1C3 seems not to play any important role in metabolism of 
either doxorubicin or oracin. To analyze the expression of AKR1C3 and CBR1 gene in 
control and drug-treated MCF-7 cells, relative quantification of mRNA using real-time 
RT-PCR was carried out. The exposure of MCF-7 cells to doxorubicin or oracin led to a 
non-significant increase of AKR1C3 and CBR1 mRNA levels. We assume that 
induction of CBR1 is caused by non-transcriptional mechanisms. In conclusion, 
identification of drug-inactivating enzymes in specific tumor tissue and mechanisms of 
their induction could contribute to explanation of drug-resistance. 
